Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for Interstitial Pneumonia in Anti-MDA5 Antibody-Positive Dermatomyositis
jRCTs031220641Suspended
- Start
- Apr 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of baricitinib in dermatomyositis-associated interstitial lung disease (DM-ILD) and dermatomyositis (DM). Primary endpoint: Incidence and rate of Grade 3 or higher adverse events. Started Apr 2024; status: suspended.
02
Drugs
baricitinib
03
Conditions
dermatomyositis-associated interstitial lung disease (DM-ILD)dermatomyositis (DM)
Beyond the preview
Go deeper on jRCTs031220641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220641.